EP Patent

EP4559463A1 — Edaravone or its salts for use in the treatment of oxidative stress-mediated neurodegenerative disorders

Assigned to Ferrer Internacional SA · Expires 2025-05-28 · 1y expired

What this patent protects

Edaravone or a pharmaceutically acceptable salt thereof is disclosed for use in the treatment of an oxidative stress-mediated neurodegenerative disorder, wherein the treatment comprises orally or gastrically administering any of them to human subjects in need thereof once daily i…

USPTO Abstract

Edaravone or a pharmaceutically acceptable salt thereof is disclosed for use in the treatment of an oxidative stress-mediated neurodegenerative disorder, wherein the treatment comprises orally or gastrically administering any of them to human subjects in need thereof once daily in the morning, at a daily dose ranging from 80 to 120 mg, during an uninterrupted period of at least 1 month, wherein the human subjects have fasted for at least 2 hours before administration.

Drugs covered by this patent

Patent Metadata

Patent number
EP4559463A1
Jurisdiction
EP
Classification
—
Expires
2025-05-28
Drug substance claim
No
Drug product claim
No
Assignee
Ferrer Internacional SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.